463 patents
Page 4 of 24
Utility
Cell Penetrating Protein-antibody Conjugates and Methods of Use
10 Aug 23
Provided herein are cell penetrating conjugates.
Andreas Herrmann, Hua Yu
Filed: 11 Apr 23
Utility
MVA vaccine for delivery of a UL128 complex and preventing CMV infection
8 Aug 23
In one embodiment, an expression system for expressing a UL128 complex is provided herein.
Don J. Diamond, Felix Wussow
Filed: 20 Nov 20
Utility
Nir-conjugated Tumor-specific Antibodies and Uses Thereof
3 Aug 23
Disclosed is a tumor-specific antibody and fluorophore conjugate for detecting, localizing and imaging of various tumors.
Paul YAZAKI, Jack SHIVELY, Michael BOUVET, Jonathan DELONG, Yuman FONG
Filed: 26 Jan 23
Utility
Composition and Method for Activating Latent Human Immunodeficiency Virus (Hiv)
3 Aug 23
Provided are compositions and methods for activating latent Human Immunodeciency Virus (HIV).
Kevin V. Morris, Marc S. Weinberg, Tristan Scott, Daniel Lazar
Filed: 14 Feb 23
Utility
SYNTHETIC MODIFIED VACCINIA ANKARA (sMVA) BASED CORONAVIRUS VACCINES
27 Jul 23
Disclosed are synthetic MVA-based vaccines for preventing or treating infections caused by a coronavirus or variants thereof.
Don J. DIAMOND, Felix WUSSOW, Flavia CHIUPPESI
Filed: 14 Sep 22
Utility
Biomarkers for cancer immunotherapy outcomes
25 Jul 23
Provided herein, inter alia, are improved methods and systems of determining immunotherapy response in subjects prior and during treatment.
Andrea Bild, Jason I. Griffiths
Filed: 2 Dec 20
Utility
Oncolytic Virus Compositions and Methods for the Treatment of Cancer
20 Jul 23
Provided herein, inter alia, are compositions and methods including recombinant oncolytic viruses expressing CD47 antibody for the treatment of diseases including cancer, immune disorders, and infectious disease.
Jianhua Yu, Michael A. Caligiuri
Filed: 6 Feb 21
Utility
Methods, Treatment, and Compositions for Characterizing Thyroid Nodule
20 Jul 23
The current disclosure provides, inter alia, method of determining benign nodules from thyroid cancer in a subject that is found to have a thyroid nodule, method of treating thyroid cancer in a subject detected to have thyroid cancer by the method of the current disclosure, compositions for determining benign nodules from thyroid cancer in a subject, and kits including reagents and composition for determining benign nodules from thyroid cancer in a subject.
Maria A. Hahn, John H. Yim, Yuman Fong, Arthur X. Li, Xiwei Wu
Filed: 20 Jul 22
Utility
Chimeric antigen receptors and methods for reducing toxicity
18 Jul 23
Nucleic acid molecules that include a nucleotide sequence encoding a chimeric antigen receptor (CAR) and a nucleotide sequence encoding a protease sensitive scFv, wherein the chimeric antigen receptor comprises: an scFv targeting a tumor antigen, a spacer, a transmembrane domain, a co-stimulatory domain, and a CD3ζ signaling domain; and the protease-sensitive scFv and the scFv target the same tumor antigen are described.
Xiuli Wang, Stephen J. Forman, Lawrence Stern, Christine E. Brown, Joseph Cohen
Filed: 25 Jan 19
Utility
Microrna As a Therapeutic Agent
13 Jul 23
The disclosure provides, inter alia, hybridized nucleic acid sequences and compounds comprising Toll-like receptor 9-binding nucleic acid sequences and nucleic acid sequences comprising a microRNA passenger strand sequence hybridized to a microRNA guide strand sequence; pharmaceutical compositions comprising the hybridized nucleic acid sequences and compounds; and the use of the hybridized nucleic acid sequences, compounds, and pharmaceutical compositions to treat medical conditions, such as cancer and inflammatory diseases.
Marcin Tomasz Kortylewski, Guido Marcucci, Yu-Lin Su, Piotr Marek Swiderski
Filed: 25 Nov 20
Utility
Nanoparticle-cell construct with platinum anti-cancer agent
11 Jul 23
The disclosure provides, inter alia, compositions including cell-nanoparticle constructs and drug loaded nanoparticles, and methods for their use in the treatment of cancer.
Pengpeng Cao, Jacob Berlin, Karen Aboody, Rachael Mooney, Wafa Abidi
Filed: 28 Dec 16
Utility
Methods for Organoids Production
6 Jul 23
Disclosed are methods of producing organoids in the absence of any exogenous extracellular matrix or in the presence of an exogenous extracellular matrix at a concentration lower than gelling concentration, using microcontainers sealed with a hydrogel lid as well as organoids produced by this technique.
Mark LABARGE, Michael TODHUNTER
Filed: 22 Apr 21
Utility
Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy
4 Jul 23
Provided herein are, inter alia, methods and compositions including T cells expressing (i) a recombinant CAR protein which includes a peptide binding site and is capable of specifically binding cancer-specific antigens and (ii) a T cell receptor specific for a viral antigen (e.g., a CMV pp65 protein).
John C. Williams, Christine Brown, Don J. Diamond
Filed: 2 Sep 21
Utility
Multi-conjugates Comprising Multiple Ligands
29 Jun 23
A multi-conjugate comprising two or more covalently linked biological subunits, wherein at least two of the subunits are terminally located targeting ligands.
Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Jonathan Miles Brown, Kristin K.H. Neuman
Filed: 1 Sep 22
Utility
Detection and treatment of neurological diseases
27 Jun 23
Disclosed are methods of detecting abnormal expression of one or more genes associated with a neurological disease such as the Alexander disease, the Alzheimer's disease, the Parkinson disease, the Huntington disease, multiple sclerosis, and amyotrophic lateral sclerosis.
Yanhong Shi, Li Li
Filed: 8 Jul 19
Utility
Hand-held grasping device
30 May 23
A hand tool has a pivot connection pivotally attaching a first arm to a second arm, with the pivot connection fixed relative to the first arm and movable to first and second positions relative to the second arm.
Gagandeep Singh
Filed: 25 Sep 20
Utility
Cell penetrating protein-antibody conjugates and methods of use
30 May 23
Provided herein are cell penetrating conjugates.
Andreas Herrmann, Hua Yu
Filed: 5 Aug 16
Utility
Epstein-barr Virus Antibodies and Uses Thereof
25 May 23
Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more epitopes of EBV gp350 and neutralize EBV infection.
Javier Gordon OGEMBO, Lorraine Zvichapera MUTSVUNGUMA, Alison Evelynn ONDRUS
Filed: 29 Jul 22
Utility
FLT3-TARGETED Chimeric Antigen Receptor Modified Cells for Treatment of FLT3-POSITIVE Malignancies
25 May 23
Provided are compositions comprising a population of autologous or allogeneic cells transduced by a nucleic acid molecule encoding a chimeric antigen receptor (CAR) specifically recognizes and binds FMS-like tyrosine kinase 3 (FLT3), methods of formulating preparing such CAR expressing cells and methods of use as anti-cancer agents.
Michael Caligiuri, Jianhua Yu
Filed: 16 Apr 21
Utility
Cell-receptor Targeted Exosomes
18 May 23
Provided herein are, inter alia, recombinant fusion proteins and exosomes comprising recombinant fusion proteins; wherein the recombinant fusion proteins comprises exosome membrane-associated proteins and exogenous target proteins; pharmaceutical compositions; and methods of using the recombinant fusion proteins, exosomes, and pharmaceutical compositions to treat diseases such as cancer, HIV, and COVID-19.
Kevin Morris, Tristan Scott
Filed: 12 Apr 21